Alterity Therapeutics Files 6-K, Incorporates into Registration Statements
Ticker: PRNAF · Form: 6-K · Filed: Feb 28, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Feb 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, shareholder-meeting, registration-statement
Related Tickers: ATHE
TL;DR
Alterity Therapeutics (ATHE) filed a 6-K on Feb 28, 2025, including a shareholder meeting notice, and it's being rolled into their S-8/F-3 filings.
AI Summary
Alterity Therapeutics Ltd. filed a Form 6-K on February 28, 2025, to report on activities for the month of February 2025. This filing incorporates by reference into several of their existing Registration Statements on Form S-8 and Form F-3. The report includes Exhibit 99.1, which is a Notice of Extraordinary General Meeting/Proxy Form.
Why It Matters
This filing indicates ongoing corporate actions and regulatory compliance, potentially affecting investors' understanding of the company's structure and future filings.
Risk Assessment
Risk Level: low — This is a routine reporting form (6-K) that incorporates previous filings and announces a shareholder meeting, not indicating new material financial events.
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Registrant
- February 2025 (date) — Reporting period
- 20250228 (date) — Filing date
- Form S-8 (document) — Incorporated by reference into
- Form F-3 (document) — Incorporated by reference into
- Exhibit 99.1 (document) — Included in filing
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is filed for the month of February 2025 and incorporates by reference into Alterity Therapeutics' existing Registration Statements on Form S-8 and Form F-3, and includes a Notice of Extraordinary General Meeting/Proxy Form.
Which Registration Statements is this 6-K being incorporated into?
This 6-K is being incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
What is the specific exhibit included with this filing?
The filing includes Exhibit 99.1, which is a Notice of Extraordinary General Meeting/Proxy Form.
What is the principal executive office address of Alterity Therapeutics Limited?
The principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Does Alterity Therapeutics file annual reports under Form 20-F or Form 40-F?
Alterity Therapeutics indicates it files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on February 28, 2025 regarding ALTERITY THERAPEUTICS LTD (PRNAF).